Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Fokas, MD, and Minali Nigam, MD. [LISTEN TIME: 21 minutes]
|Slideshows|May 3, 2019
Migraine Update: 7 Recent Developments
Author(s)Leo Robert
Cognitive deficits are gender based, opioids complicate prophylactic treatment, patients with migraine seen by ophthalmologists-find concise summaries of these and other findings here.
Advertisement
Advertisement
Related to this article
Alit Stark-Inbar, PhD, Chief Scientific Officer of Theranica, writes about migraine prevention beyond lifestyle changes, highlighting the role of neuromodulation and other evidence-based treatments in long-term management.
A review of 12 studies showed that maternal migraine was linked to a higher likelihood of infant colic, and that infant colic was in turn linked to a higher risk of migraine later in childhood.
The phase 3 LUNA study showed that atogepant, an oral calcitonin gene-related peptide receptor antagonist, significantly reduced perimenstrual migraine days among patients with menstrual migraine compared with placebo.
The AAN and AHS have replaced their 2012 migraine prevention guideline with new, evidence-graded recommendations, giving neurologists clearer direction on when to start preventive therapy, how to choose among older and newer options, and how to adjust treatment for specific patients.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
4
Episode 175: Advancing the Ways of Treating Cluster Headache
5